





The daunting disease of cancer owe its origin to numerous complex genetic and 
non-genetic factors, both intrinsic and extrinsic.  Despite the century old efforts from 
scientists and physicians across the globe for finding cure for this deadly disease, long 
term cure without any relapse of tumor remains elusive.  The hallmarks of most, if not 
all, types of cancer include: self-sufficiency in growth signals, resistance to growth 
suppressors, evading apoptosis, limitless proliferation, inducing angiogenesis, invasion 
& metastasis, reprogramming energy metabolism and lastly, evading the host’s immune 
system. Clinical success of most of the contemporary cancer therapies are limited due to 
non-availability of highly tumor specific drug delivery systems leading to adverse side 
effects on various non-cancerous healthy body tissues, insufficient bioavailability of 
many potent cancer therapeutics, drug resistivity, and the poor physicochemical 
properties of many anti-cancer drugs. To overcome these challenges, chemotherapeutic 
drugs (single or combination) or genetic drugs are often delivered selectively to the 
diseased site with the help of ligand coated liposomal or polymeric drug delivery 
systems for targeting drugs to cancer cells via receptors over expressed selectively on 
the exo-surfaces of  cancer cells. The current thesis embodies design, synthesis, physico-
chemical characterizations, bio-activity evaluations of two novel ligand-coated 
liposomal drug delivery systems for treatment of pancreatic cancer and lung carcinoma. 
Furthermore, the findings of the present thesis demonstrate for the first time that 
liposomally targeted chemotherapy, when used in combination with in vivo dendritic 
cell (DC), targeted DNA vaccination elicits markedly enhanced overall survivability of 
orthotopic pancreatic and lung carcinoma-bearing mice.  
Statement of the problem 
Cancer has long been considered to be a profoundly complex disease with 
second highest mortality rate treatable only with blunt approaches that frequently do as 
much damage to the patient as to the tumor. Pancreatic cancer is often detected late, 
spreads rapidly, and has a poor prognosis. After diagnosis, 25% of people survive one 
year and 5% live for five years.  In an estimated 53,070 new cases of pancreatic cancer, 
41,780 death of pancreatic cancer patients have been reported in 2016.  Lung cancer is 
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the number one cause of cancer deaths in both men and women in the U.S. and 
worldwide. The vast majority (85%) of cases of lung cancer are due to long-
term tobacco smoking. The general prognosis of lung cancer is poor because doctors 
tend not to find the disease until it is at an advanced stage. Five-year survival is around 
54% for early stage lung cancer that is localized to the lungs, but only around 4% in 
advanced, inoperable lung cancer. Lung cancer occurred in 1.8 million people and 
resulted in 1.6 million deaths Worldwide in 2012. Thus, there is an urgent need for 
developing novel and more competent approach for eradicating and enhancing the 
overall survival rate of both pancreatic and lung cancer patients using targeted 
chemotherapy and cancer immunotherapy. 
Objectives of the study 
1. To develop the plectin-1 receptor (plec) targeting  liposomal formulations of 
novel plectin-1 selective KTLLPTP-lipopeptide and to evaluate their therapeutic 
promises in combating orthotopic mouse pancreatic cancer using our newly 
developed approach of combining targeted chemotherapy and direct in vivo DC-
targeted DNA vaccination. 
2. To develop lung cancer targeting liposomal formulations of novel SNIDARAK-
lipopeptide & its non-targeting control NSSSVDKK-lipopeptide and to evaluate 
their therapeutic promises in combating orthotopic mouse lung cancer using our 
newly developed approach of combining targeted chemotherapy and direct in 
vivo DC-targeted DNA vaccination. 
3. Structure-activity studies on the use of liposomes of mono-, di-, and tri-
guanidinylated cationic amphiphiles for systemic co-delivery of potent anti-
cancer drugs paclitaxel (PTX) & CDC20 siRNA co-encapsulated within the 
liposomes of these guanidinylatd amphiphiles using an orthotopic mouse lung 
tumor model. 
Methodologies Used and Sample Results 
Part 1 describes development of the plectin1-targeting liposomal formulations of 
lipopeptide containing phase display derived pancreatic cancer targeting ligan 
KTLLPTP in the head group region (lipopeptide 1) and its nontargeting control 
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lipopeptide with SNLHPSD in the head group region (lipopeptide 2). The fluorescently 
labeled liposomal formulations of lipopeptide 1 showed higher cellular uptake in 
pancreatic cancer cells (Pan02, Panc-1, and Miapaca-2) compared to normal NIH3T3 
Cells. Plectin-1 receptor selective cellular uptake process for these liposomal formutions 
were confirmed by antibody saturation. The ex vivo fluorescence values of isolated 
organs revealed that mice injected with NIR-labeled liposomal formulation of 
lipopeptide 1 had strong fluorescence in the orthotopic pancreatic tumor compared to 
other isolated organs. Importantly, combination of i.v. administration of the liposomal 
formulation of lipopeptide-1 containing both curcumin & gemcitabine and genetic 
immunization with in vivo DCs targeting lipoplex of liposomes of mannose-mimicking 
cationic amphiphile (recently developed in our laboratory) & p-CMV-MSLN (a plasmid 
DNA encoding mesothelin expressed in the majority of pancreatic cancer cells) 
regressed and increased survivability of the established orthotopic mouse pancreatic 
tumor model in syngeneic C57BL/6J mice. The findings in CTL assay and cytokines 
assay (IFN-γ & IL-4) clearly demonstrated that the in vivo DCs targeted lipoplexes were 







































































































































































































The Part 2 of the present thesis describes design of a novel lung cancer targeting 
liposomal formulations of SNIDARA-lipopeptide (lipopeptide 1) and its non-targeting 
control lipopeptide with NSSSVDK in the head group region (lipopeptide 2). Further, 
this parts embodies development of a novel liposomal delivery system prepared using 
the above-mentioned lipopeptides for lung cancer targeted delivery of curcumin and 
doxorubicin. The labeled liposomal formulation of lipopeptide 1 showed higher cellular 
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uptake in lung cancer cells (LLC, H460, and A549) compared to normal NIH3T3 Cells. 
The ex vivo fluorescence values  of isolated organs revealed that mice injected with 
doxorubicin loaded  liposomal formulation of lipopeptide 1 had strong fluorescence in 
the orthotopic pancreatic tumor compared to other isolated organs. Findings in the MTT-
assay basedcCell viability studies and annexin-v binding based apoptosis studies 
demonstrated that co-delivery of curcumin and doxorubicin loaded targeted liposomes 
maximally enhanced the anti-cancer effect. The same result was also found during cell 
cycle study where curcumin and doxorubicin delivery via targeting liposome exhibited 
maximum G2/M population. Importantly, combination of i.v. administration of the 
liposomal formulation of lipopeptide-1 containing both curcumin & doxorubicin and 
immunization with in vivo DCs targeting lipoplex of mannose-mimicking cationic 
amphiphile (recently developed in our lab) & p-CMV-MUC-1 (a plasmid DNA 
encoding MUC-1 expressed in the majority of lung cancer cells) regressed and increased 
survivability of the established orthotopic mouse lung tumor model in syngeneic 
C57BL/6J mice. 
Part 3 of the present thesis embodies structure activity studies using different 
liposomal formulations of mono-, di- and tri- guanidinylated cationic amphiphiles 
containing co-encapsulated anti-cancer drugs and genes. PTX (hydrophobic drug) was 
solubilized within the lipid bilayer regions of the liposomes and CDC20 siRNA 
(hydrophilic anti-cancer siRNA) was encapsulated within the aqueous core of the 
liposomal formulations. Bio-activities of the liposomal formulations of these cationic 
guanidinylated amphiphiles were evaluated both in vitro and in vivo. Biodistribution 
studies using FAM-siRNA labeled liposomes revealed orthotopic mouse lung tumour 
selective accumulation of the liposomal formulations in syngeneic C57BL/6J mice.  The 
plasma stability of FAM-siRNA labeled liposomes, MTT-based cytotoxicity assays, 
Annexin-V binding based apoptosis studies and cell cycle arrest at G2M phase were 
studied.  Finally, in vivo tumor inhibition and survival studies were done with the most 
efficient liposomal formulation containg both PTX and CDC20 siRNA in orthotopic 
mouse lung tumor model. Importantly, the findings in these structure-activity studies 
convincingly demonstrated that presence of more positive charge (due to presence of 3 
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guanidine groups in the head-group region) can enhance the entrapment efficiency of 
drugs and genes, and increase the plasma stability of the liposomal formulations. 
 

































































































The findings described in the present thesis collectively demonstrate that  use of 
tumor-targeted liposomal drug delivery in combination with in vivo dendritic cell 
targeted DNA vaccination leads to remarkable survivability enhancements in orthotopic 
pancreatic and lung tumor bearing mice. Such combination therapy holds potential for 
future use as a “platform technology” in the war against the dreaded disease of cancer. 
